Efficiency of CYP2C9 Genetic Test Representation for Automated Pharmacogenetic Decision Support

被引:12
|
作者
Deshmukh, V. G. [1 ]
Hoffman, M. A. [2 ]
Arnoldi, C. [2 ]
Bray, B. E. [1 ]
Mitchell, J. A. [1 ]
机构
[1] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT 84112 USA
[2] Cerner Corp, Kansas City, MO USA
关键词
Pharmacogenetics; clinical decision support systems; SNP; allele; CYTOCHROME-P450; CYP2C9; DOSE REQUIREMENT; WARFARIN; METABOLISM; GENOMICS; ANTICOAGULATION; THERAPY;
D O I
10.3414/ME0570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives: We investigated the suitability of representing discrete genetic test results in the electronic health record (EHR) as individual single nucleotide polymorphisms (SNPs) and as alleles, using the CYP2C9 gene and its polymorphic states, as part of a pilot study. The purpose of our investigation was to determine the appropriate level of data abstraction when reporting genetic test results in the EHR that would allow meaningful interpretation and clinical decision support based on current knowledge, while retaining sufficient information in order to enable reinterpretation of the results in the context of future discoveries. Methods: Based on the SNP & allele models, we designed two separate lab panels within the laboratory information system, one containing SNPs and the other containing alleles, built separate rules in the clinical decision support system based on each model, and evaluated the performance of these rules in an EHR simulation environment using real-world scenarios. Results: Although decision-support rules based on allele model required significantly less computational time than rules based on SNP model, no difference was observed on the total time taken to chart medication orders between rules based on these two models. Conclusions: Both, SNP- and allele-based models, can be used effectively for representing genetic test results in the EHR without impacting clinical decision support systems. While storing and reporting genetic test results as alleles allow for the construction of simpler decision-support rules, and make it easier to present these results to clinicians, SNP-based model can retain a greater amount of information that could be useful for future reinterpretation.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 50 条
  • [41] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
    Daly, Ann K.
    Rettie, Allan E.
    Fowler, Douglas M.
    Miners, John O.
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (01):
  • [42] Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations
    Castelan-Martinez, Osvaldo D.
    Hoyo-Vadillo, Carlos
    Sandoval-Garcia, Emmanuel
    Sandoval-Ramirez, Lucila
    Gonzalez-Ibarra, Miriam
    Solano-Solano, Gloria
    Gomez-Diaz, Rita A.
    Parra, Esteban J.
    Cruz, Miguel
    Valladares-Salgado, Adan
    GENE, 2013, 523 (02) : 167 - 172
  • [43] CYP2C9 polymorphism studies in the Saudi population
    Saour, Jalal N.
    Shereen, Atia W.
    Saour, Basil J.
    Mammo, Layla A.
    SAUDI MEDICAL JOURNAL, 2011, 32 (04) : 347 - 352
  • [44] CYP2C9 and CYP2C19 genetic polymorphisms:: frequencies in the south Indian population
    Jose, R
    Chandrasekaran, A
    Sam, SS
    Gerard, N
    Chanolean, S
    Abraham, BK
    Satyanarayanamoorthy, K
    Peter, A
    Rajagopal, K
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) : 101 - 105
  • [45] Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
    Nastasi-Catanese, J. A.
    Padilla-Gutierrez, J. R.
    Valle, Y.
    Ortega-Gutierrez, F.
    Gallegos-Arreola, M. P.
    Figuera, L. E.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (04) : 4413 - 4421
  • [46] Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
    Sagrieya, Hersh
    Berube, Caroline
    Wen, Alice
    Ramakrishnan, Ramesh
    Mir, Alain
    Hamilton, Amy
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (07) : 407 - 413
  • [47] Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone
    Kaori Matsumoto
    Tetsuya Hasegawa
    Kosuke Ohara
    Chihiro Takei
    Masayuki Akimoto
    Journal of Pharmaceutical Investigation, 2020, 50 : 71 - 79
  • [48] Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment
    Jose Cerezo-Manchado, Juan
    Roldan, Vanessa
    Rosafalco, Mario
    Isabel Anton, Ana
    Belen Arroyo, Ana
    Garcia-Barbera, Nuria
    Belen Martinez, Ana
    Padilla, Jose
    Corral, Javier
    Vicente, Vicente
    Gonzalez-Conejero, Rocio
    PHARMACOGENOMICS, 2014, 15 (07) : 987 - 996
  • [49] Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone
    Matsumoto, Kaori
    Hasegawa, Tetsuya
    Ohara, Kosuke
    Takei, Chihiro
    Akimoto, Masayuki
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2020, 50 (01) : 71 - 79
  • [50] Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
    Ota, Tomoko
    Kamada, Yuka
    Hayashida, Mariko
    Iwao-Koizumi, Kyoko
    Murata, Shigenori
    Kinoshita, Kenji
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2015, 12 (01): : 78 - 82